View Author
patient melanoma study treatment survival cancer group interferon trial ratio observation analysis prognostic month response stage eortc oncol number ferritin dacarbazine rt-pcr signi tumour adjuvant result therapy lymph temozolomide blood value sentinel disease effect factor outcome table article baseline tumor melanoma patients hazard metastasis-free survival metastatic melanoma ficant phase hospital sample research model cytogenetic metastatic event journal pegylated level observation group sn tumour burden difference university ulceration oncology leukemia randomised randomisation criteria metastasi metastase aberration density children european autoimmunity interferon group serum thickness induction 6 months metastasis-free analyses
10 Most Recent Publications
|
Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study)
(Article)
Busse, A. Rapion, J. Spatz, A. Eggermont, A.M.M. Keilholz, U. Fusi, A. Suciu, S. Nonnenmacher, A. Santinami, M. Kruit, W.H.J. Testori, A. Punt, C.J.A. Dalgleish, A.G. |
2013-04-29
|
|
Prognosis in patients with sentinel node-positive melanoma without immediate completion lymph node dissection
(Article)
Ploeg, A.P.T. van der Akkooi, A.C.J. van Rutkowski, P. Cook, M. Nieweg, O.E. Rossi, C.R. Testori, A. Suciu, S. Verhoef, C. Eggermont, A.M.M. |
2012-10-01
|
|
Changes of ferritin and CRP levels in melanoma patients treated with adjuvant interferon-α (EORTC 18 952) and prognostic value on treatment outcome
(Article)
Bouwhuis, M.G. Collette, S. Suciu, S. Groot, E.R. de Kruit, W.H.J. Hagen, T.L.M. ten Aarden, L.A. Eggermont, A.M.M. Swaak, A.J.G. |
2011-08-01
|
|
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032)
(Article)
Patel, P. Suciu, S. Becker, J. Conry, R. Thompson, J.A. Hwu, W.-J. Agarwala, S.S. Engelen, K. Keilholz, U. Eggermont, A.M.M. Spatz, A. Mortier, L. Kruit, W.H.J. Robert, C. Schadendorf, D. Trefzer, U. Punt, C.J.A. Dummer, R. Davidson, N. |
2011-07-01
|
|
Autoimmunity and treatment outcome in melanoma
(Article)
Bouwhuis, M.G. Hagen, T.L.M. ten Suciu, S. Eggermont, A.M.M. |
2011-03-01
|
|
Reply to F. Janku et al
(Article)
Eggermont, A.M.M. Bottomley, A. Suciu, S. Coens, C. Testori, A. Patel, P. Spatz, A. |
2010-01-10
|
|
Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study)
(Article)
Fusi, A. Collette, S. Spatz, A. Eggermont, A.M.M. Keilholz, U. Busse, A. Suciu, S. Rietz, A. Santinami, M. Kruit, W.H.J. Testori, A. Punt, C.J.A. Dalgleish, A.G. |
2009-12-01
|
|
LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951)
(Article)
Agarwala, S.S. Keilholz, U. Gilles, E. Bedikian, A.Y. Wu, J. Kay, R. Stein, C.A. Itri, L.M. Suciu, S. Eggermont, A.M.M. |
2009-07-01
|
|
Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon
(Article)
Bouwhuis, M.G. Suciu, S. Hernberg, M. Spatz, A. Hagen, T.L.M. ten Hansson, J. Eggermont, A.M.M. Collette, S. Aamdal, S. Kruit, W.H.J. Bastholt, L. Stierner, U. Sals, F. Patel, P. Punt, C.J.A. |
2009-06-01
|
|
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
(Article)
Eggermont, A.M.M. Suciu, S. Kusic, Z. Dummer, R. Hauschild, A. Musat, E. Spatz, A. Keilholz, U. Santinami, M. Testori, A. Kruit, W.H.J. Marsden, J. Punt, C.J.A. Salès, F. Gore, M. MacKie, R.M. |
2008-07-14
|
